Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-17
2005-05-17
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S263200, C514S263300, C514S263220, C544S265000, C544S276000, C544S118000
Reexamination Certificate
active
06894045
ABSTRACT:
Compounds provided herein are novel substituted tetrahydropurinones of Formula (I):wherein R3is aryl substituted with 0-5 XAror heteroaryl substituted with 0-4 XhAr. Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.
REFERENCES:
patent: 6004966 (1999-12-01), Singh
patent: 6310205 (2001-10-01), Chasin et al.
patent: 0856310 (1998-08-01), None
patent: WO 9510506 (1995-04-01), None
patent: WO 9601761 (1996-01-01), None
patent: WO 9735539 (1997-10-01), None
patent: WO 9735846 (1997-10-01), None
patent: WO 9744308 (1997-11-01), None
patent: WO 9803510 (1998-01-01), None
patent: WO 9901439 (1999-01-01), None
patent: WO 9901454 (1999-01-01), None
patent: WO 9911643 (1999-03-01), None
patent: WO 9918707 (1999-04-01), None
patent: WO 9951608 (1999-10-01), None
patent: WO 0001675 (2000-01-01), None
patent: WO 0219975 (2002-03-01), None
J. Rivier et. al., Proc. Nat. Acad. Sci. (USA), 80:4851 (1983).
W. Vale et al., Science 213:1394 (1981).
W. Vale et al., Rec. Prog. Horm. Res. 39:245 (1983).
G.F. Koob, Persp. Behav. Med. 2:39 (1985).
E.D. De Souza et al., J. Neurosci. 5:3189 (1985).
J.E. Blalock, Physiological Reviews 69:1 (1989).
J.E. Morley, Life Sci. 41:527 (1987).
E.B. De Souza, Hosp. Practice 23:59 (1988).
C.B. Nemeroff et al., Science 226:1342 (1984).
C.M Banki et al., Am. J. Psychiatry 144:873 (1987).
R.D. France et al., Biol. Psychiatry 28:86 (1986).
M. Arato et al., Biol Psychiatry 25:355 (1989).
C.B. Nemeroff et al., Arch. Gen. Psychiatry 45:577 (1988).
P.W. Gold et al., Am J. Psychiatry 141:619 (1984).
F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984).
P.W. Gold et al., New Eng. J. Med. 314:1129 (1986).
R.M. Sapolsky, Arch. Gen. Psychiatry 46:1047 (1989).
Grigoriadis et al., Neuropsychopharmacology 2:53 (1989).
D.R. Britton et al., Life Sci. 31:363 (1982).
C.W. Berridge and A.J. Dunn, Regul. Peptides 16:83 (1986).
C.W. Berridge and A.J. Dunn, Horm. Behav. 21:393 (1987).
Dunn, Brain Research Reviews 15:71 (1990).
K.T. Britton et al., Psychopharmacology 86:170 (1985).
K.T. Britton et al., Psychopharmacology 94:306 (1988).
N.R. Swerdlow et al., Psychopharmacology 88:147 (1986).
G.F. Koob and K.T. Britton, In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E.B. De Souza and C.B. Nemeroff eds., CRC press p221 (1990).
C. Maillot, M. Million, J.Y. Wei, A. Gauthier, Y. Tache, Gastroenterology, 119, 1569-1979 (2000).
J.R. McCarthy, S.C. Heinrichs and D.E. Grigoriadis, Cuur. Pharm. Res., 5, 289-315 (1999).
P.J. Gilligan, D.W. Robertson and R. Zaczek, J. Medicinal chem., 43, 1641-1660 (2000).
G.P. Chrousos, Int. J. Obesity, 24, Suppl. S50-S55 (2000).
E. webster, D.J. Torpy, I.J. Elenkov, G.P. Chrousos, Ann,N.Y. Acad. Sci., 840, 21-32 (1988).
D.J. Newport and C.B. Nemeroff, Curr. Opin. Neurobiology, 10, 211-218 (2000).
G. Mastorakos and I. Ilias, Ann N.Y. Acad. Sci., 900, 95-106 (2000).
M.J. Owens and C.B. Nemeroff, Expert Opin. Invest. Drugs, 8 1849-1858 (1999).
G.F. Koob, Ann N.Y. Acad. Sci., 909, 170-185 (2000).
Remington's Pharmaceutical Sciences, 17thed., Mack Publishing Company, Easton, PA, 1985, p. 1418.
Wolfe, J.P.; Tomori, H.; Sadighi, J.P.; Yin, J.; Bushwald, S.L., J. Org. Chem. 2000, 65,1158-1174.
Berch Mark L.
Bristol-Myers Squibb Pharma Company
Goddard Christine A.
Makujina Shah R.
Woodcook Washburn LLP
LandOfFree
Tetrahydropurinones and derivatives thereof as corticotropin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydropurinones and derivatives thereof as corticotropin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydropurinones and derivatives thereof as corticotropin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463695